Friday, August 28, 2015

Sunoco, Cephalon both involved in international deals

The oil refiner sold its chemicals business to a Brazilian firm, while the biopharmaceutical company bought a Swiss generic drug maker.

Sunoco, Cephalon both involved in international deals


There certainly was an international accent to the deals announced yesterday involving Philadelphia-area companies.

A Brazilian company bought Sunoco Inc.’s polypropylene business for $350 million. Braskem S.A. is buying a foothold in the huge U.S. chemicals market from Philadelphia’s Sunoco.

In the other deal, Frazer-based Cephalon Inc. bought a Swiss generic-drug maker for $590 million. The transaction is the latest move by a pharmaceutical company to become less reliant on the U.S. market for its sales.

The purchase of Mepha AG will double the size of Cephalon’s international business. The privately held Mepha had sales of about 400 million Swiss francs, or about $379 million, in 2009.

For its nine months ended Sept. 30, Cephalon generated $266.3 million in net sales in Europe compared with $1.35 billion in the United States.

Mepha employs 1,000 people worldwide, including 500 in Switzerland. Expected to close in the next 12 weeks, the deal would bring Cephalon’s global workforce to about 3,800.


David Pernock has been named chief executive officer of Fibrocell Science Inc., a small Exton company that’s been developing a wrinkle treatment.

Until November, Pernock had been a senior vice president at GlaxoSmithKline P.L.C. in the Philadelphia area.

Pernock, 55, was chairman of Fibrocell when it emerged from bankruptcy on Sept. 3. He replaces interim CEO Declan Daly, who is now chief financial officer.

In December, the FDA issued a “complete response letter” regarding Fibrocell’s wrinkle treatment. That means that the company will have to supply more information before the agency can consider possible approval.


Stated another way, even if TARP saved our financial system from driving off a cliff back in 2008, absent meaningful reform, we are still driving on the same winding mountain road, but this time in a faster car.

- from a quarterly report to Congress issued Saturday by the Office of the Special Inspector General for the Troubled Asset Relief Program.

Inquirer Columnist
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at

Mike Armstrong Inquirer Columnist
Also on
letter icon Newsletter